Clinical Trial Update: A Randomized, Open-label, Double-cohort Study of Fluzoparib Combined With Famitinib Malate or SHR-1701 for Neoadjuvant Therapy in Patients With Advanced Ovarian Cancer [Phase 2]

View source ↗

Summary

Phase 2 randomized neoadjuvant trial evaluating Fluzoparib in combination with Famitinib Malate or SHR-1701 for advanced ovarian cancer; the study status is not…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Famitinib malate (famitinib malate)
• Fluzoparib (fluzoparib)
• SHR-1701

Snippet

Sponsor: Qinglei Gao | Conditions: Ovarian Cancer | Phase 2 | Status: NOT_YET_RECRUITING